Johannesburg ian graham dating 90 search ghana dating

29-Jul-2015 04:37

In response, the EAS launched the FH Studies Collaboration (FHSC) [ an international registry of observational studies on FH. Catapano, University of Milan, Italy: The FHSC aims to provide information on how patients are currently screened and managed, what are the barriers to effective treatment, as well as the impact of patient-specific, genetic, and societal factors on treatment efficacy.The FHSC is led by Professor Kausik Ray, Imperial College, London UK:; to date more than 30 countries have already agreed to take part.EAS Congress also provided tantalising insights into a forthcoming Consensus Panel statement focused on Paediatric FH.

While some have questioned the veracity of SAMS given that clinical trials have failed to differentiate any difference in myalgia rates between patients allocated statin or placebo, in routine clinical practice it is clear that there is an issue, with SAMS reported by almost 30% of patients on statins.

Furthermore, data from the Framingham Offspring Cohort clearly show that even exposure to moderately elevated cholesterol is a strong predictor of future CVD events; after 15 years follow-up, CHD rates were about 4-fold higher in individuals with 11-20 years exposure to elevated cholesterol compared with those with no exposure before age 55 years.[6] Professor John Deanfield, University College Hospital, London, UK:, argued that individuals should be empowered to accept personal responsibility for their arteries and risk of heart disease: .

Targeting lifestyle earlier, in young adulthood, is therefore critical.

Such a move highlights the need for effective public education about lifestyle and a means to ensure the sustainability of intervention.

The Joint British Societies has adopted a personalised, lifetime approach to risk using the Heart Age Tool, with understandable risk metrics, which allows patients to see the impact of lifestyle interventions on their heart age.[7] Professor Deanfield also discussed new opportunities for a lifetime risk approach, with much interest in assessment of brain aging.

While some have questioned the veracity of SAMS given that clinical trials have failed to differentiate any difference in myalgia rates between patients allocated statin or placebo, in routine clinical practice it is clear that there is an issue, with SAMS reported by almost 30% of patients on statins.

Furthermore, data from the Framingham Offspring Cohort clearly show that even exposure to moderately elevated cholesterol is a strong predictor of future CVD events; after 15 years follow-up, CHD rates were about 4-fold higher in individuals with 11-20 years exposure to elevated cholesterol compared with those with no exposure before age 55 years.[6] Professor John Deanfield, University College Hospital, London, UK:, argued that individuals should be empowered to accept personal responsibility for their arteries and risk of heart disease: .

Targeting lifestyle earlier, in young adulthood, is therefore critical.

Such a move highlights the need for effective public education about lifestyle and a means to ensure the sustainability of intervention.

The Joint British Societies has adopted a personalised, lifetime approach to risk using the Heart Age Tool, with understandable risk metrics, which allows patients to see the impact of lifestyle interventions on their heart age.[7] Professor Deanfield also discussed new opportunities for a lifetime risk approach, with much interest in assessment of brain aging.

Kees Hovingh, Academic Medical Center, Amsterdam, the Netherlands:.